Difference between revisions of "Colorectal cancer, BRAF-mutated"
Jump to navigation
Jump to search
Ryannguyen (talk | contribs) |
Ryannguyen (talk | contribs) |
||
| Line 52: | Line 52: | ||
*[[Cetuximab (Erbitux)]] 250 mg/m<sup>2</sup> IV over 60 minutes on days 8, 15, 22 | *[[Cetuximab (Erbitux)]] 250 mg/m<sup>2</sup> IV over 60 minutes on days 8, 15, 22 | ||
| − | '''28-day cycle, | + | '''28-day cycle, continued indefinitely''' |
===References=== | ===References=== | ||
# '''BEACON:''' Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. [https://www.nejm.org/doi/full/10.1056/NEJMoa1908075 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/31566309 PubMed] | # '''BEACON:''' Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. [https://www.nejm.org/doi/full/10.1056/NEJMoa1908075 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/31566309 PubMed] | ||
| + | |||
| + | ==Vemurafenib, Irinotecan, and Cetuximab {{#subobject:1a2d3b|Regimen=1}}== | ||
| + | |||
| + | {| class="wikitable" style="width: 100%; text-align:center;" | ||
| + | !style="width: 25%"|Study | ||
| + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 25%"|Comparator | ||
| + | !style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| + | |- | ||
| + | |[https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.520 Kopetz et al. 2017 (SWOG 1406)] | ||
| + | |style="background-color:#1a9851"|Phase II | ||
| + | | Cetuximab & Irinotecan | ||
| + | | style="background-color:#91cf60" |Seems to have superior PFS | ||
| + | |- | ||
| + | |} | ||
| + | ====Chemotherapy==== | ||
| + | *[[Vemurafenib (Zelboraf)]] 960 mg PO twice per day on days 1 through 14 | ||
| + | *[[Irinotecan (Camptosar)]] 180mg/m<sup>2</sup> IV on day 1 | ||
| + | *[[Cetuximab (Erbitux)]] 500 mg/m<sup>2</sup> IV on day 1 | ||
| + | |||
| + | '''14-day cycle, continued indefinitely''' | ||
| + | |||
| + | ===References=== | ||
| + | # '''SWOG 1406:''' Kopetz S, McDonough S, Morris V, Lenz HJ, Magliocco A, Atreya C, Diaz L, Allegra C, Lieu C, Wang S, Eckhardt SG, Semrad T, Kaberle K, Guthrie K, Hochster H. Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG1406). DOI: 10.1200/JCO.2017.35.4_suppl.520 Journal of Clinical Oncology 35, no. 4_suppl (February 01, 2017) 520-520. Published online March 21, 2017.[https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.520 link to original article] | ||
[[Category:Colon cancer regimens]] | [[Category:Colon cancer regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Colorectal cancers]] | [[Category:Colorectal cancers]] | ||
Revision as of 07:08, 6 November 2019
| Section editor | |
|---|---|
 |
Neeta K. Venepalli, MD, MBA University of Illinois at Chicago Chicago, IL |
Note: the page has regimens specific to BRAF-mutated colon cancer.
- See the main colon cancer page for general regimens.
4 regimens on this page
5 variants on this page
|
Guidelines
ESMO
- 2016: Van Cutsem et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. PubMed
Older
- 2013: Labianca et al. Early Colon Cancer: ESMO Clinical Practice Guidelines PubMed
- 2013: Balmaña et al. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. PubMed
Japanese Society for Cancer of the Colon and Rectum
- 2016: Watanabe et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer PubMed
NCCN
SIOG
- 2014: Papamichael et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013
Advanced or metastatic disease, second or third-line therapy
Encorafenib, Binimetinib, and Cetuximab
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Kopetz et al. 2019 (BEACON) | Phase III | 1. Cetuximab & Irinotecan 2. Cetuximab & FOLFIRI |
Seems to have superior OS |
Chemotherapy
- Encorafenib (Braftovi) 300 mg PO once per day on days 1 through 28
- Binimetinib (Mektovi) 45mg PO twice per day on days 1 through 28
- Cetuximab (Erbitux) 400 mg/m2 IV over 120 minutes on day 1
- Cetuximab (Erbitux) 250 mg/m2 IV over 60 minutes on days 8, 15, 22
28-day cycle, continued indefinitely
References
- BEACON: Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. link to original article contains verified protocol PubMed
Vemurafenib, Irinotecan, and Cetuximab
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Kopetz et al. 2017 (SWOG 1406) | Phase II | Cetuximab & Irinotecan | Seems to have superior PFS |
Chemotherapy
- Vemurafenib (Zelboraf) 960 mg PO twice per day on days 1 through 14
- Irinotecan (Camptosar) 180mg/m2 IV on day 1
- Cetuximab (Erbitux) 500 mg/m2 IV on day 1
14-day cycle, continued indefinitely
References
- SWOG 1406: Kopetz S, McDonough S, Morris V, Lenz HJ, Magliocco A, Atreya C, Diaz L, Allegra C, Lieu C, Wang S, Eckhardt SG, Semrad T, Kaberle K, Guthrie K, Hochster H. Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG1406). DOI: 10.1200/JCO.2017.35.4_suppl.520 Journal of Clinical Oncology 35, no. 4_suppl (February 01, 2017) 520-520. Published online March 21, 2017.link to original article